Who owns Krystal Biotech, Inc. (KRYS)? Elite investor 13F holders
4 tracked elite investors reported holding Krystal Biotech, Inc as of 2026-09-30, including Bridgewater Associates, Renaissance Technologies LLC, Torray Funds, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Bridgewater Associates | KRYSTAL BIOTECH INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 33229395.00 USD | 99920.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | KRYSTAL BIOTECH INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 20991187.00 USD | 63120.000000 | Shares | add | Original filing |
| Torray Funds | KRYSTAL BIOTECH INC | SHARE | 2026-09-30 | 2026-10-30 00:00:00 | 2783527.00 USD | 8370.000000 | Shares | reduce | Original filing |
| Gotham Asset Management | KRYSTAL BIOTECH INC | SHARE | 2026-09-30 | 2026-11-16 00:00:00 | 441307.00 USD | 1327.000000 | Shares | reduce | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.